Through this study, we expect to further uncover the clinical application potential of CD133‐positive CTCs as a biomarker in stage I patients of NSCLC, thereby providing a scientific basis for optimizing treatment strategies and improving patient survival rates. Here, PROM1 is linked to non-small cell lung carcinoma.